BCM
ACET icon

Bayesian Capital Management’s Adicet Bio ACET Stock Holding History

Bayesian Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-789
Closed -$18.2K – 654
2024
Q3 		$18.2K Sell
789
-737
-48% -$16.5K ﹤0.01% 639
2024
Q2 		$29.5K Sell
1,526
-875
-36% -$23.4K ﹤0.01% 676
2024
Q1 		$90.3K Buy
+2,401
New +$99.3K 0.01% 719
2023
Q1 		– Sell
-1,400
Closed -$200K – 746
2022
Q4 		$200K Buy
+1,400
New +$349K 0.03% 601

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Bayesian Capital Management's ACET Position: Q4 2024 in Review

Bayesian Capital Management sold out of Adicet Bio (ACET) in Q4 2024, closing a stake of 789 shares — an estimated $18.2K sold.

Bayesian Capital Management first reported a position in ACET in Q4 2022 and held it in 4 quarters. The position peaked at $200K in Q4 2022. 64 funds tracked by Wall St. Rank hold ACET as of Q4 2024.

  • Bayesian Capital Management reported no remaining Adicet Bio position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 789 Adicet Bio shares in Q4 2024, an estimated $18.2K.
  • Bayesian Capital Management first reported a position in Adicet Bio in Q4 2022 and held it in 4 quarters.
  • Bayesian Capital Management's Adicet Bio position peaked at $200K in Q4 2022.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.